Cell Genesys (CEGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1129)	5/20/2001 8:47:57 PM
From: Madharry	Read Replies (1) of 1298

I think that your methodology is a good starting point but we have to adjust for where these different companies are in the development cycle and how they will have to access funds to proceed with their development. It seems to me that CEGE has lot of options. there is no urgency for them to liquidate their abgx stake at all. they only need to liquidate enough to offset their r&D costs. then it will be tax free. They could use their cash to purchase biotech companies in their field that are cash hungry. IMHO CEGE should be at a premium to comparable companies because of their financial resources. i have seen too many companies with promising technologies either go belly up or be acquired for a very low price because they lacked the resources to stay the course independently.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next